325 related articles for article (PubMed ID: 12093249)
41. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.
Waters EA; McNeel TS; Stevens WM; Freedman AN
Breast Cancer Res Treat; 2012 Jul; 134(2):875-80. PubMed ID: 22622807
[TBL] [Abstract][Full Text] [Related]
42. Tamoxifen and raloxifene may benefit women at high risk for breast cancer.
Rollins G
Rep Med Guidel Outcomes Res; 2002 Jul; 13(14):1-2, 5. PubMed ID: 12518771
[No Abstract] [Full Text] [Related]
43. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
[TBL] [Abstract][Full Text] [Related]
44. Recruitment of women into trials.
Benson JR
Lancet; 2002 Jan; 359(9301):164. PubMed ID: 11809281
[No Abstract] [Full Text] [Related]
45. Breast cancer prevention in high-risk women: searching for new options.
Nelson NJ
J Natl Cancer Inst; 2011 May; 103(9):710-1. PubMed ID: 21515834
[No Abstract] [Full Text] [Related]
46. Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices--counterpoint.
Fabian C
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2210-2. PubMed ID: 18006909
[No Abstract] [Full Text] [Related]
47. Toward optimal health: advances in breast cancer detection and management. Interview by Jodi R. Godfrey.
Chlebowski RT
J Womens Health (Larchmt); 2008 Sep; 17(7):1067-70. PubMed ID: 18774890
[No Abstract] [Full Text] [Related]
48. Chemoprevention of breast cancer.
Dalton RR; Kallab AM
South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
[TBL] [Abstract][Full Text] [Related]
49. Future possibilities in the prevention of breast cancer: breast cancer prevention trials.
Cuzick J
Breast Cancer Res; 2000; 2(4):258-63. PubMed ID: 11250718
[TBL] [Abstract][Full Text] [Related]
50. Arzoxifene: a promising new selective estrogen receptor modulator for clinical chemoprevention of breast cancer.
Sporn MB
Clin Cancer Res; 2004 Aug; 10(16):5313-5. PubMed ID: 15328166
[No Abstract] [Full Text] [Related]
51. Breast cancer chemoprevention: a review of selective estrogen receptor modulators.
Johansen AM
Clin J Oncol Nurs; 2005 Jun; 9(3):317-20. PubMed ID: 15973842
[TBL] [Abstract][Full Text] [Related]
52. Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.
Kondo M; Hoshi SL; Toi M
Jpn J Clin Oncol; 2009 Nov; 39(11):767-70. PubMed ID: 19656807
[TBL] [Abstract][Full Text] [Related]
53. Prevention of breast cancer: current state of the science and future opportunities.
Uray IP; Brown PH
Expert Opin Investig Drugs; 2006 Dec; 15(12):1583-600. PubMed ID: 17107283
[TBL] [Abstract][Full Text] [Related]
54. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.
Freedman AN; Graubard BI; Rao SR; McCaskill-Stevens W; Ballard-Barbash R; Gail MH
J Natl Cancer Inst; 2003 Apr; 95(7):526-32. PubMed ID: 12671020
[TBL] [Abstract][Full Text] [Related]
55. Effects of high dose raloxifene in selected patients with advanced breast carcinoma.
Gradishar W; Glusman J; Lu Y; Vogel C; Cohen FJ; Sledge GW
Cancer; 2000 May; 88(9):2047-53. PubMed ID: 10813716
[TBL] [Abstract][Full Text] [Related]
56. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Wolmark N
Clin Breast Cancer; 2002 Jun; 3(2):153-9. PubMed ID: 12123540
[TBL] [Abstract][Full Text] [Related]
57. Raloxifene examined for breast cancer prevention.
Young D
Am J Health Syst Pharm; 2007 Sep; 64(17):1774. PubMed ID: 17724350
[No Abstract] [Full Text] [Related]
58. Risk-benefit profiles of women using tamoxifen for chemoprevention.
Nichols HB; DeRoo LA; Scharf DR; Sandler DP
J Natl Cancer Inst; 2015 Jan; 107(1):354. PubMed ID: 25475563
[TBL] [Abstract][Full Text] [Related]
59. Tamoxifen: the herald of a new era of preventive therapeutics.
Jordan VC
J Natl Cancer Inst; 1997 Jun; 89(11):747-9. PubMed ID: 9182965
[No Abstract] [Full Text] [Related]
60. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Land SR; Wickerham DL; Costantino JP; Ritter MW; Vogel VG; Lee M; Pajon ER; Wade JL; Dakhil S; Lockhart JB; Wolmark N; Ganz PA
JAMA; 2006 Jun; 295(23):2742-51. PubMed ID: 16754728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
